AFP announces new bureau in North Korea
Agence France-Presse (AFP) announced Tuesday it will open a bureau in Pyongyang, becoming only the second global news agency to establish a permanent presence in the North Korean capital.
Brussels (AFP) | 10/07/2025 - 12:58:18 | EU strikes deal with Israel to 'expand' aid access to Gaza: Kallas
Rome (AFP) | 10/07/2025 - 12:41:15 | Merz urges Trump to 'stay with us' Europeans on Ukraine
Dubai (AFP) | 10/07/2025 - 12:37:51 | Saudi Arabia executed over 100 foreigners in 2025 so far: AFP tally
Kuala Lumpur (AFP) | 10/07/2025 - 12:31:16 | Rubio meets with Russia's Lavrov in Malaysia
Gaza City (AFP) | 10/07/2025 - 12:26:22 | Gaza civil defence says number killed by Israeli forces rises to 52
Rome (AFP) | 10/07/2025 - 12:17:52 | Zelensky urges more investment in defence against Russian attacks
Strasbourg (AFP) | 10/07/2025 - 12:14:33 | EU chief survives confidence vote by large margin
Geneva (AFP) | 10/07/2025 - 12:11:42 | Rights council president says 'regrets' US sanctions on UN expert
Kyiv (AFP) | 10/07/2025 - 11:59:41 | Ukraine civilian casualties in June hit three-year high: UN
Moscow (AFP) | 10/07/2025 - 11:58:30 | Kremlin denies Ukraine peace process has stalled
Agence France-Presse (AFP) announced Tuesday it will open a bureau in Pyongyang, becoming only the second global news agency to establish a permanent presence in the North Korean capital.
AFP takes part to the 7th photography festival in Leipzig f/stop, Germany, from June 25th until July 3rd, 2016.
The Asian Productivity Organization (APO) convened the 67th Session of the Governing Body (GBM), 20–22 May 2025 in Jakarta, hosted by the Government of the Republic of Indonesia. This annual session brought together over 50 delegates representing APO member governments to discuss the APO’s strategic direction and ensure the organization’s continued credibility, effectiveness, and relevance amid a rapidly evolving productivity landscape. This press release features multimedia. View the full rel...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice® fully human antibody platform family. It underscores the continued advancement of Biocytogen’s comprehensive ...